In short
This article discusses the ongoing clinical trials of Mva-209-Fsp-B1, a component of the Nous-209 genetic vaccine. This innovative treatment is being studied for patients with advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. The trials aim to assess the vaccine's effectiveness when combined with pembrolizumab, an immunotherapy drug, in treating this specific type of colorectal cancer.
At a glance
- Drug Name
- Mva-209-Fsp-B1 (part of Nous-209 genetic vaccine)
- Trial Phase
- Phase I/II
- Target Condition
- Advanced MSI-H or dMMR Colorectal Cancer
- Administration
- Intramuscular injection
- Combination Therapy
- With pembrolizumab (immunotherapy)
- Primary Endpoint
- Overall Response Rate (ORR)
- Secondary Endpoints
- Safety, tolerability, Best Overall Response, Duration of Response, Progression-Free Survival
- Key Eligibility Criteria
- Adults with confirmed MSI-H/dMMR colorectal cancer, adequate organ function, life expectancy ≥6 months
What is MVA-209-FSP?
MVA-209-FSP is an experimental genetic vaccine being studied for the treatment of advanced colorectal cancer. It is specifically designed for patients whose cancer has a characteristic called "microsatellite instability-high" (MSI-H) or "mismatch repair deficient" (dMMR). These terms describe genetic features of the cancer that make it potentially responsive to this type of treatment.
The vaccine is made up of four components, known as MVA-209-FSP-B1, MVA-209-FSP-B2, MVA-209-FSP-B3, and MVA-209-FSP-B4. Each of these components is based on a modified version of a virus called Modified Vaccinia Ankara (MVA), which has been engineered to be safe for use in humans.
How does MVA-209-FSP work?
MVA-209-FSP works by introducing genetic material into the body that encodes for 209 specific proteins called Frame Shift Peptides (FSPs). These FSPs are abnormal proteins that are often found in MSI-H/dMMR cancers but not in normal cells. By presenting these proteins to the immune system, the vaccine aims to "train" the body's defenses to recognize and attack cancer cells that produce these abnormal proteins.
The vaccine is given by intramuscular injection, meaning it's injected directly into a muscle. This method of administration helps to stimulate a strong immune response.
Who is this treatment for?
MVA-209-FSP is being studied in patients with:
- Advanced colorectal cancer: This includes cancer that is locally advanced (has spread to nearby tissues) and cannot be surgically removed, or metastatic (has spread to other parts of the body).
- MSI-H or dMMR status: These are specific genetic characteristics of the tumor that must be confirmed through testing.
- Age 18 or older.
Clinical Trial Details
The clinical trial for MVA-209-FSP is a Phase I/II study, which means it's in the early stages of testing in humans. The study is designed to:
- Evaluate the safety and tolerability of the vaccine when given in combination with another drug called pembrolizumab (an immunotherapy drug).
- Assess how well the treatment works in shrinking or controlling the growth of tumors.
The trial includes different groups of patients:
- Some who have not previously received immunotherapy treatment.
- Some who have previously received immunotherapy but whose cancer has progressed.
Potential Benefits
While it's important to remember that MVA-209-FSP is still experimental, the researchers hope to see the following benefits:
- Shrinkage of tumors or slowing of tumor growth.
- Longer periods without the cancer getting worse (progression-free survival).
- Potentially improved outcomes for patients who have not responded to or have progressed after other treatments.
Safety Considerations
As with any experimental treatment, there are potential risks and side effects. The clinical trial is designed to carefully monitor patients for any adverse reactions. Some important safety considerations include:
- Patients must have adequate organ function and blood test results to participate in the trial.
- Certain medical conditions or prior treatments may exclude someone from participating in the trial.
- Patients who are pregnant, breastfeeding, or planning to become pregnant cannot participate.
- The trial excludes people with certain active infections or immune system disorders.
It's crucial for patients to discuss all potential risks and benefits with their healthcare team before considering participation in this or any clinical trial.